Navigation Links
Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
Date:9/2/2010

t Takeda Pharmaceuticals North America, Inc. and Takeda Global Research & Development Center, Inc.

Based in Deerfield, Ill., Takeda Pharmaceuticals North America, Inc. and Takeda Global Research & Development Center, Inc. are subsidiaries of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. The respective companies currently market oral diabetes, insomnia, rheumatology and gastroenterology treatments and seek to bring innovative products to patients through a pipeline that includes compounds in development for diabetes, cardiovascular disease, gastroenterology, neurology and other conditions. To learn more about these Takeda companies, visit www.tpna.com.

Forward-Looking Statements Related to Orexigen

Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are based on the Company's current beliefs and expectations. These forward-looking statements include statements regarding the potential for, and timing of, approval for Contrave, the Company's belief that this product candidate may be an important therapeutic option in the treatment of obesity, the potential milestone and royalty payments under the agreement with Takeda and the potential strength of our market entry with Contrave, if approved. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: Orexigen's dependence on
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Orexigen® Therapeutics COR-BMOD Study Published in the Journal Obesity
2. Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
3. Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
4. Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity
5. Reportlinker Adds Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets
6. Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
7. Echo Therapeutics Announces Successful Completion of Clinical Trial for Prelude™ SkinPrep System and 4% Lidocaine Cream
8. BioMarin Acquires ZyStor Therapeutics, Inc.
9. Nile Therapeutics Reports 2010 Second Quarter Financial Results
10. Cornerstone Therapeutics Announces Development of Generic for Tussionex®
11. Cornerstone Therapeutics Licenses Alpha-7 Technology to Targacept
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... LONDON , BERLIN ... Arthroscopy Devices Market to ... for Minimally Invasive Procedures to Drive Future Growth" looks ... for the six arthroscopy device market segments: arthroscopes, arthroscopy ... radio frequency systems, and arthroscopy visualization systems. The report ...
(Date:5/20/2013)... , May 20, 2013  Rhythm announced today ... demonstrating a higher prevalence of gastroparesis symptoms among diabetic ... these symptoms is high among patients with both type ... significantly under-diagnosed among those with the more common type ... , MD, PhD, Associate Professor of Medicine at ...
(Date:5/20/2013)... NORTH CHICAGO, Ill. , May 20, 2013 ... today the initiation of a Phase 3 clinical ... Atrasentan) to assess the effects of the investigational ... on progression of kidney disease in patients with ... and type 2 diabetes.  SONAR is a large, ...
Breaking Medicine Technology:Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 2Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 3Increasing Prevalence of Osteoarthritis and Preference for Minimally Invasive Procedures to Drive Arthroscopy Devices Market Growth 4Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 2Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 3Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 2AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 3AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 5AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 6
... 17, 2011 OxySure Systems, Inc., a pioneering ... powder technology, today announced that the Company has ... City of Frisco, Texas, to deliver its life-saving ... multiple Frisco municipal and community service facilities. ...
... CRANBURY, N.J., Oct. 17, 2011 Sen. ... leaders of the biopharmaceutical industry Friday unveiled the state-of-the-art ... part, by the U.S. Affordable Care Act. ... "We are committed to advancing innovative and improved biotherapeutics ...
Cached Medicine Technology:OxySure Inks 5-Year Partnership With the City of Frisco to Place OxySure/AED Packages in Its Public Venues 2OxySure Inks 5-Year Partnership With the City of Frisco to Place OxySure/AED Packages in Its Public Venues 3Senator Menendez, Lt. Governor Guadagno Unveil New Biotech Firm Oncobiologics 2Senator Menendez, Lt. Governor Guadagno Unveil New Biotech Firm Oncobiologics 3
(Date:5/20/2013)... yurbuds®, maker of the sport earphones ... the launch of its new Signature Series ITE 100 ... more signature athletes to come. Created with top players ... 100 is the perfect training partner for any athlete. ... reflective, tangle-resistant Kevlar cords, premium sound quality and a ...
(Date:5/20/2013)... Nearly 20 percent of kidneys that are recovered from ... due to factors ranging from scarring in small blood ... going too long without blood or oxygen. But, what ... "recycled" to help solve the critical shortage of donor ... and colleagues, reporting in the journal Biomaterials , ...
(Date:5/20/2013)... 2013 Dorland Health, a division ... fourth annual Case In Point Platinum Awards, recognizing ... ensuring the system is patient- and family-centric, safe ... and creative work across the healthcare system that ... transitions of care through effective care coordination across ...
(Date:5/20/2013)... Chicago (PRWEB) May 20, 2013 The ... raise $5,000 for Bright Pink®, the organization that empowers young ... by the end of 2012. Thanks to its members, ASCP ... Patterson, HT(ASCP), is involved in Relay for Life at the ... Bright Pink, he decided to donate. “I was made aware ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 ... cloud and on-premise business process integration solutions, ... of its next-generation integration solution. Version ... solution that seamlessly automates business processes involving ... with meaningful business user interaction for real-time ...
Breaking Medicine News(10 mins):Health News:yurbuds Expands Best-Selling Lines with Innovative New Products 2Health News:Study suggests new source of kidneys for transplant 2Health News:Dorland Health Announces the 2013 Case In Point Platinum Awards Winners 2Health News:ASCP Members Rally Around Breast and Ovarian Cancer Awareness 2Health News:ASCP Members Rally Around Breast and Ovarian Cancer Awareness 3Health News:Adeptia Announces New Release of Enterprise Business Integration Solution 2Health News:Adeptia Announces New Release of Enterprise Business Integration Solution 3
... Southwestern Medical Center cardiologists have uncovered how a specific protein,s ... in patients with diabetes. Investigators in the mouse study also ... this protein. The new research, available online and published ... Clinical Investigation , was carried out in the laboratory of ...
... , THURSDAY, March 1 (HealthDay News) --,An estimated 4 million ... year, a new study found. A little less than 1 ... from the U.S. Forest Service used satellite imagery to analyze the ... by pavement, rooftops, grass or bare soil in 20 U.S. cities. ...
... University of North Carolina at Chapel Hill reduced damage from ... protein found in mice and humans. The study, in which ... protein focal adhesion kinase, or FAK, appeared March 1 in ... Vascular Biology . "This study shows that we can ...
... HealthDay Reporter , THURSDAY, March 1 (HealthDay News) ... their risk of developing the deadly skin cancer melanoma, a ... A called retinol could be a protective agent against melanoma; ... say. "We found a protective effect from supplemental vitamin ...
... March 1 (HealthDay News) -- White men in the United ... black men, while white women live more than five years ... when the University of California, Los Angeles-led team of researchers ... surprising discovery: In states where disparities were smallest, the differences ...
... , THURSDAY, March 1 (HealthDay News) -- Where ... have found, with city dwellers tweeting at a higher pitch ... of controlled sound recordings, researchers from the University of Copenhagen ... change the way they sing due to city buildings -- ...
Cached Medicine News:Health News:Cardiologists identify mechanism that makes heart disease worse in diabetics 2Health News:Urban Forests Disappearing: Report 2Health News:A supercharged protein reduces damage from heart attack 2Health News:Vitamin A Supplements Might Cut Melanoma Risk: Study 2Health News:Vitamin A Supplements Might Cut Melanoma Risk: Study 3Health News:Life Expectancy for U.S. Blacks Shorter Than That of Whites 2Health News:City Birds Sing Differently Than Their Country Cousins 2
... LCD color monitor ... of the icons for ... your desired choices for ... measure much smaller pupils ...
Portable, easy to align, automatic measurement, automatic fogging. Accurate and dependable readings. Infrared printer communication. Rechargeable battery. Integrates with the TRS-2100 and EPIC-2100 r...
... frequency doubled Nd:YAG laser is mounted on ... be selected between 0.2 and 2.0 mJ. ... 400 and 700 microns. Knobs for laser ... located on the laser head. The laser ...
... II Glaucoma Laser System features a patented ... open-angle glaucoma. It selectively targets pigmented cells ... The Selecta II is equipped with a ... of light, which induces the same cell ...
Medicine Products: